DK3433368T3 - Transreplikerende rna - Google Patents

Transreplikerende rna Download PDF

Info

Publication number
DK3433368T3
DK3433368T3 DK17710268.8T DK17710268T DK3433368T3 DK 3433368 T3 DK3433368 T3 DK 3433368T3 DK 17710268 T DK17710268 T DK 17710268T DK 3433368 T3 DK3433368 T3 DK 3433368T3
Authority
DK
Denmark
Prior art keywords
transreplicating
rna
transreplicating rna
Prior art date
Application number
DK17710268.8T
Other languages
English (en)
Inventor
Tim Beissert
Ugur Sahin
Mario Perkovic
Original Assignee
BioNTech SE
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical BioNTech SE
Application granted granted Critical
Publication of DK3433368T3 publication Critical patent/DK3433368T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07048—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK17710268.8T 2016-03-21 2017-03-13 Transreplikerende rna DK3433368T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2016/056160 WO2017162265A1 (en) 2016-03-21 2016-03-21 Trans-replicating rna
PCT/EP2017/055813 WO2017162461A1 (en) 2016-03-21 2017-03-13 Trans-replicating rna

Publications (1)

Publication Number Publication Date
DK3433368T3 true DK3433368T3 (da) 2021-11-15

Family

ID=55586324

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17710268.8T DK3433368T3 (da) 2016-03-21 2017-03-13 Transreplikerende rna

Country Status (26)

Country Link
US (2) US12338448B2 (da)
EP (2) EP3964584A1 (da)
JP (2) JP7105193B2 (da)
KR (1) KR102441725B1 (da)
CN (2) CN109328233B (da)
AU (1) AU2017236240B2 (da)
BR (1) BR112018068391A2 (da)
CY (1) CY1124689T1 (da)
DK (1) DK3433368T3 (da)
ES (1) ES2896927T3 (da)
HR (1) HRP20211715T1 (da)
HU (1) HUE058889T2 (da)
IL (1) IL261327B2 (da)
LT (1) LT3433368T (da)
MA (1) MA44479B1 (da)
MD (1) MD3433368T2 (da)
MX (1) MX2018011384A (da)
PL (1) PL3433368T3 (da)
PT (1) PT3433368T (da)
RS (1) RS62543B1 (da)
RU (1) RU2752580C2 (da)
SG (1) SG11201807378SA (da)
SI (1) SI3433368T1 (da)
SM (1) SMT202100634T1 (da)
WO (2) WO2017162265A1 (da)
ZA (2) ZA201805520B (da)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
AU2018333530B2 (en) * 2017-09-13 2024-05-30 Biontech Cell & Gene Therapies Gmbh RNA replicon for expressing a T cell receptor or an artificial T cell receptor
US12291717B2 (en) 2017-09-13 2025-05-06 Biontech Rna Pharmaceuticals Gmbh RNA replicon for reprogramming somatic cells
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
US10736957B2 (en) 2017-12-19 2020-08-11 President And Fellows Of Harvard College Enhanced immunogenicity of mRNA with co-encoded adjuvant sequences
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
EP3990648A1 (en) * 2019-06-27 2022-05-04 EMD Millipore Corporation Cell expansion with self-replicating rna vectors expressing immortalization proteins
KR102764120B1 (ko) 2019-12-31 2025-02-06 엘릭서젠 쎄라퓨틱스, 인크. 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달
EP4103228A1 (en) 2020-02-13 2022-12-21 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
KR102462990B1 (ko) 2020-03-17 2022-11-07 에이비온 주식회사 인비트로 트랜스크립트 mRNA 및 이를 함유하는 약학조성물
EP4171629A1 (en) 2020-06-29 2023-05-03 GlaxoSmithKline Biologicals S.A. Adjuvants
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
GB202020061D0 (en) 2020-12-17 2021-02-03 Imp College Innovations Ltd RNA construct
GB202020064D0 (en) 2020-12-17 2021-02-03 Imperial College Innovations Ltd RNA construct
GB202020063D0 (en) 2020-12-17 2021-02-03 Imperial College Innovations Ltd RNA construct
CN112852841A (zh) * 2021-02-03 2021-05-28 郑州大学 一种高效表达目的蛋白的顺式复制子rna构建体
EP4313152A1 (en) 2021-03-26 2024-02-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
JP2024518335A (ja) 2021-04-26 2024-05-01 アンスティチュ パスツール ＳＡＲＳ－ＣｏＶ－２に対するヒト中和モノクローナル抗体、及びそれらの使用
WO2022234268A1 (en) * 2021-05-04 2022-11-10 Mogrify Limited Cell conversion
US20240285755A1 (en) 2021-05-24 2024-08-29 Glaxosmithkline Biologicals Sa Adjuvants
US12570977B2 (en) * 2021-06-12 2026-03-10 Mello Biotech Taiwan Co., Ltd. mRNA composition and production method for use in anti-viral and anti-cancer vaccines
AU2022294274A1 (en) 2021-06-18 2024-02-01 Sanofi Pasteur Inc. Multivalent influenza vaccines
EP4376883A4 (en) * 2021-07-30 2025-07-16 Arcturus Therapeutics Inc RNA VACCINES
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
US20240350410A1 (en) 2021-08-16 2024-10-24 Glaxosmithkline Biologicals Sa Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
US20250134824A1 (en) 2021-08-16 2025-05-01 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
CN115960922A (zh) * 2021-10-09 2023-04-14 吴可行 自复制rna分子设计及其应用
EP4419708A1 (en) 2021-10-18 2024-08-28 BioNTech SE Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
EP4169578A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide compounds and complexes
EP4186528A1 (en) 2021-11-30 2023-05-31 BioNTech SE Oligosaccharide complexes and uses
EP4286394A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide compounds and complexes
EP4286004A1 (en) 2022-05-30 2023-12-06 BioNTech SE Disulfide oligosaccharide compounds and complexes
EP4169580A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide compounds and complexes
EP4285933A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide complexes and uses
US20250002522A1 (en) 2021-10-22 2025-01-02 BioNTech SE Oligosaccharide compounds and complexes
EP4286003A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide compounds and complexes
EP4285932A1 (en) 2022-05-30 2023-12-06 BioNTech SE Oligosaccharide complexes and uses
WO2023067121A1 (en) 2021-10-22 2023-04-27 BioNTech SE Oligosaccharide compounds and complexes
EP4169534A1 (en) 2021-10-22 2023-04-26 BioNTech SE Oligosaccharide complexes and uses
JP2024543721A (ja) 2021-10-22 2024-11-22 ビオンテック・ソシエタス・エウロパエア オリゴ糖複合体及び用途
EP4169579A1 (en) 2021-10-22 2023-04-26 BioNTech SE Disulfide oligosaccharide compounds and complexes
JP2024540979A (ja) 2021-10-22 2024-11-06 ビオンテック・ソシエタス・エウロパエア オリゴ糖複合体及び用途
EP4402149A1 (en) 2021-10-22 2024-07-24 BioNTech SE Disulfide oligosaccharide compounds and complexes
US20230302112A1 (en) 2021-11-05 2023-09-28 Sanofi Respiratory synctial virus rna vaccine
WO2023083434A1 (en) 2021-11-09 2023-05-19 BioNTech SE Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
CA3242439A1 (en) 2021-12-17 2023-06-22 Sanofi Lyme disease rna vaccine
WO2023214082A2 (en) 2022-05-06 2023-11-09 Sanofi Signal sequences for nucleic acid vaccines
US20250375534A1 (en) 2022-05-30 2025-12-11 BioNTech SE Complexes for delivery of nucleic acids
JP2025529906A (ja) 2022-08-22 2025-09-09 ザ ヘンリー エム ジャクソン ファンデイション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド コロナウイルスに対するワクチン
JP2025532191A (ja) 2022-09-26 2025-09-29 ビオンテック・ソシエタス・エウロパエア 核酸複合体及びその使用
WO2024086549A1 (en) * 2022-10-17 2024-04-25 The University Of North Carolina At Chapel Hill Chimeric alphaviruses for directed evolution
EP4605010A1 (en) 2022-10-21 2025-08-27 BioNTech SE Nucleic acid complexes and uses thereof
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
KR20250099727A (ko) 2022-11-04 2025-07-02 사노피 파스퇴르 인크 호흡기 세포융합 바이러스 rna 백신접종
US12115217B2 (en) 2022-11-18 2024-10-15 Trustees Of Boston University Self-replicating RNA and uses thereof
CN120659802A (zh) 2022-12-15 2025-09-16 赛诺菲巴斯德有限公司 mRNA重组加帽酶
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions
WO2024133550A1 (en) 2022-12-22 2024-06-27 Vector Biopharma Ag Eukaryotic self-amplifying system
EP4669348A1 (en) 2023-02-24 2025-12-31 BioNTech SE IMMUNOGENEOUS COMPOSITIONS
AR132053A1 (es) 2023-03-02 2025-05-21 Sanofi Pasteur Composiciones para su uso en el tratamiento de clamidia
EP4442276A1 (en) 2023-04-07 2024-10-09 Institut Pasteur Combined antibodies against sarbecoviruses and uses thereof
IL324411A (en) 2023-05-05 2026-01-01 Sanofi Pasteur Inc Preparations for use in the treatment of acne
US20250009865A1 (en) 2023-05-10 2025-01-09 Sanofi Combination respiratory mrna vaccines
WO2024236192A1 (en) 2023-05-17 2024-11-21 Institut Pasteur Heterodimer of poxvirus a16 and g9 proteins as an immunogen
EP4474015A1 (en) 2023-06-05 2024-12-11 Veterna Srl Noda-like rna-vaccine pharmacon and production and uses thereof
IL325951A (en) 2023-07-19 2026-03-01 Sanofi Sa Porphyromonas gingivalis antigenic constructs
TW202519509A (zh) 2023-08-01 2025-05-16 德商拜恩技術股份公司 可離子化硫脂質及其用途
WO2025026545A1 (en) 2023-08-01 2025-02-06 BioNTech SE Ionizable thioplipids and uses thereof
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response
CN122055450A (zh) * 2023-10-16 2026-05-15 韩国生命工学研究院 用于改善蛋白质翻译效率的RNA结构、包含其的mRNA结构及其用途
CN122514603A (zh) * 2023-11-02 2026-08-04 安普利特治疗公司 包含经化学修饰的核碱基的反式扩增rna
WO2025124711A1 (en) 2023-12-13 2025-06-19 BioNTech SE Glycolipid compositions
WO2025134062A2 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
WO2025134066A1 (en) 2023-12-21 2025-06-26 Biontech Delivery Technologies Gmbh Ionizable lipids
WO2025153707A1 (en) 2024-01-19 2025-07-24 Spikimm Broadly sars-cov-2 neutralizing monoclonal antibodies and uses thereof
CN120379688A (zh) * 2024-01-24 2025-07-25 南京金斯瑞生物科技有限公司 一种自复制rna及其用途
WO2025217136A2 (en) * 2024-04-08 2025-10-16 Amplitude Therapeutics, Inc. Trans-amplifying rnas encoding immunomodulators
EP4656648A1 (en) 2024-05-31 2025-12-03 Consejo Superior De Investigaciones Científicas Immunomodulatory thiourea and urea carbohydrate compounds and uses thereof
WO2025262460A1 (en) 2024-06-21 2025-12-26 BioNTech SE Lipid compositions for nucleic acid delivery
WO2026008743A1 (en) 2024-07-02 2026-01-08 Sanofi Pasteur Inc. Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
WO2026033380A1 (en) 2024-08-05 2026-02-12 BioNTech SE Process for preparing oligosaccharide complexes
EP4696782A1 (en) 2024-08-14 2026-02-18 Starvax One B.V. Improved split rna replicons
WO2026122794A1 (en) * 2024-12-05 2026-06-11 Amplitude Therapeutics, Inc. Eeev replicase trans-amplifying rnas

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101818145A (zh) * 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
EP1165811A2 (en) 1999-03-09 2002-01-02 Large Scale Biology Corporation Multiple component rna vector system for expression of foreign sequences
EP1326990B1 (en) 2000-08-29 2007-09-19 Wyeth Holdings Corporation Packaging of positive-strand rna virus replicon particles
CA2448066A1 (en) * 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles
US20030232324A1 (en) * 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
EP1490494A1 (en) 2002-04-01 2004-12-29 Walter Reed Army Institute of Research Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
EP1608762B1 (en) 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
US20090104226A1 (en) * 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
WO2008119827A1 (en) * 2007-04-02 2008-10-09 Fit Biotech Oy Transreplicase constructs
US8153773B2 (en) 2007-06-19 2012-04-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse phosphorothioate analogs of the messenger RNA cap
DK2947149T3 (da) 2007-06-21 2018-06-06 Alphavax Inc Alphavirus-replikonpartikler til anvendelse i vaccination
CN101848936B (zh) 2007-08-20 2017-05-03 葛兰素集团有限公司 生产方法
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
FI4005592T3 (fi) * 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
US9192661B2 (en) * 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
RS63890B1 (sr) 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム
EP3542789A3 (en) 2010-08-31 2020-01-01 GlaxoSmithKline Biologicals SA Lipids suitable for liposomal delivery of protein-coding rna
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
PT2750707T (pt) 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
BR112014008694A2 (pt) 2011-10-11 2017-06-20 Novartis Ag moléculas de ácido nucleico policistrônico recombinante
JP6232544B2 (ja) 2011-11-11 2017-11-22 ヴァリエーション バイオテクノロジーズ インコーポレイテッド サイトメガロウイルスの治療のための組成物及び方法
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
RU2658490C2 (ru) 2012-03-27 2018-06-21 Кьюрвак Аг Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
WO2013143698A1 (en) 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
WO2014170493A2 (en) * 2013-04-19 2014-10-23 Novartis Ag Alphavirus vector
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
EP3681901B1 (en) 2017-09-13 2024-03-27 BioNTech SE Method of enhancing rna expression in a cell

Also Published As

Publication number Publication date
KR20180127360A (ko) 2018-11-28
US20250290095A1 (en) 2025-09-18
ZA201805520B (en) 2019-11-27
CY1124689T1 (el) 2022-07-22
IL261327B1 (en) 2024-04-01
JP7105193B2 (ja) 2022-07-22
MA44479B1 (fr) 2021-11-30
SG11201807378SA (en) 2018-10-30
JP2022020634A (ja) 2022-02-01
EP3964584A1 (en) 2022-03-09
CN115386596A (zh) 2022-11-25
PT3433368T (pt) 2021-11-15
EP3433368A1 (en) 2019-01-30
EP3433368B1 (en) 2021-10-06
MA44479A (fr) 2021-04-21
WO2017162265A1 (en) 2017-09-28
WO2017162461A1 (en) 2017-09-28
JP7421256B2 (ja) 2024-01-24
RS62543B1 (sr) 2021-12-31
MD3433368T2 (ro) 2021-12-31
BR112018068391A2 (pt) 2019-01-15
CN109328233A (zh) 2019-02-12
HUE058889T2 (hu) 2022-09-28
HRP20211715T1 (hr) 2022-02-18
IL261327A (en) 2018-10-31
KR102441725B1 (ko) 2022-09-08
SMT202100634T1 (it) 2022-01-10
ES2896927T3 (es) 2022-02-28
AU2017236240A1 (en) 2018-09-20
RU2018131783A (ru) 2020-04-22
SI3433368T1 (sl) 2022-01-31
US12338448B2 (en) 2025-06-24
PL3433368T3 (pl) 2021-12-27
JP2019509048A (ja) 2019-04-04
RU2752580C2 (ru) 2021-07-29
US20200299724A1 (en) 2020-09-24
AU2017236240B2 (en) 2022-11-17
CN109328233B (zh) 2022-10-11
MX2018011384A (es) 2019-02-13
IL261327B2 (en) 2024-08-01
CA3017285A1 (en) 2017-09-28
RU2018131783A3 (da) 2020-07-14
LT3433368T (lt) 2021-11-25
ZA201905396B (en) 2021-03-31

Similar Documents

Publication Publication Date Title
LT3433368T (lt) Trans-replikuojama rnr
EP3440949A4 (en) FLAVOR INHALER
DK3405050T3 (da) Børnesikret snusbeholder
EP3446605A4 (en) HAND VACUUM
EP3445380C0 (en) BACTERIOTHERAPY
DK3436823T3 (da) Antigen-array
EP3455498A4 (en) Fuel delivery injector
EP3450133A4 (en) Liquid blow molding method
DK3335532T3 (da) Tandharve
DK3402792T3 (da) Quinolin-2-on-derivater
EP3409779A4 (en) Single-stranded oligonucleotide
EP3402022A4 (en) GRAB WIRE
EP3484035A4 (en) HYSTERESESTROMVERSORGUNGSSCHALTUNG
EP3478921A4 (en) ZUGSCHNURANORDNUNG
EP3465295A4 (en) STACK OF POLARIZERS
DK3445708T3 (da) Stigbøjle
EP3402021A4 (en) GRAB WIRE
EP3475155A4 (en) WING SAILING BOAT
DK3452590T3 (da) Plademagnet
DK3528829T3 (da) Bacitracin-alginat-oligomer-konjugater
DK3509963T3 (da) Pallecontainer
DK3575238T3 (da) Pallecontainer
EP3399976C0 (en) BENZOTHIAZOLE AMPHOPHILES
EP3473285A4 (en) Injector
DE112017000734A5 (de) Glycolsensor